Photo by austindistel from unsplash
Erythropoiesis‐stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B‐ESA), in myelofibrosis (MF) is not well established. Click to show full abstract
Erythropoiesis‐stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B‐ESA), in myelofibrosis (MF) is not well established.
Keywords:
biosimilar erythropoiesis;
erythropoiesis stimulating;
agents effective;
myelofibrosis;
stimulating agents
Journal Title: European Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!